mCRPC VL

177LU-PSMA-617 in the Treatment of Patients with Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer - Oliver Sartor

Details
Professor of Medicine Oliver Sartor from Tulane University joins Charles Ryan to discuss several lutetium studies, radioligand therapy, and the VISION trial and where the state of lutetium currently stands both in the United States and globally with radiopharmaceutical treatment options. Biographies: A. Oliver Sartor, MD, Professor of Medicine and Medical Director, Tulane Cancer Center; C. E. and...

Cabazitaxel is a New Standard of Care for Third Line Metastatic Prostate Cancer - Bertrand Tombal

Details
Bertrand Tombal presents the recently published results from the CARD trial: "CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent". Enzalutamide in Metastatic Prostate Cancer (mCRPC) is highly heterogeneous with the coe...

A Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer - The VISION Trial, Interview with Oliver Sartor

Details
Oliver Sartor joins Charles Ryan to talk about the VISION trial, a trial testing the PSMA-617 agent, The novel therapeutic drug 177 Lu-PSMA-617 is a prostate-specific membrane antigen (PSMA) targeting agent to deliver radionuclide therapy for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The primary objective of this study is to compare the 2 alternative e...

Guiding First Line Treatment Decisions for mCRPC After ADT + Docetaxel or AR Pathway Inhibitor - Mary-Ellen Taplin

Details
Mary-Ellen Taplin joins Alicia Morgans to share highlights from her 2019 Advanced Prostate Cancer Consensus Conference (APCCC) presentation on first line treatment of metastatic castration-resistant prostate cancer (mCRPC) after patients have received either docetaxel or abiraterone, enzalutamide, or apalutamide and the lack of data to guide treating physicians in this treatment setting. She highl...

Clinical Trial Treatment Options for Rare GU Malignancies - Bradley McGregor

Details
Alicia Morgans and Brad McGregor discuss rare genitourinary histologies and the efforts to find treatment options for populations not always included in clinical trials. Most clinical trials are developed and designed for the most common subtypes, not including atypical variant histologies often found in bladder and prostate cancers. Given the tumor agnostic approach of immunotherapy, Brad and his...

A Study Evaluating Optimal Use of Radioactive Drugs for Prostate Cancer Therapy - Misha Beltran

Details
Misha Beltran shares details on the Department of Defense grant, a collaboration with Scott Tagawa and Neil Bander at Weill Cornell, and now a continuing effort at the Dana-Farber Cancer Institute. This grant is providing funding to really hone in on the therapeutic side of who are the patients most likely to benefit from PSMA scanning. Focusing on better treatment options for these patients and w...

Radium-223 in Clinical Practice - Phillip J. Koo

Details
Phill Koo joins Neal Shore to discuss radium 223 for treating men with metastatic castration-resistant prostate cancer. Radium-223 has improved overall survival (OS) and reduced symptomatic skeletal events (SSE) in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases (ALSYMPCA trial). The survival benefit and the safety and tolerability profile of radium-223 we...

Decreased Fracture Rate When Adding Bone Protecting Agents to Radium-223: PEACE III- Bertrand F. Tombal

Details
Bertrand Tombal discusses the ongoing PEACE III trial evaluating enzalutamide alone versus enzalutamide plus radium-223 post the ERA-223 data. The interim safety analysis was presented at ASCO and the data demonstrated that there was an increase fracture rate with the addition of radium-223 to enzalutamide prior to mandating the use of bone protecting agents. Pathological and non-pathological frac...

Contemporary Sequencing in the Treatment of Prostate Cancer - Neal Shore, Alicia Morgans and Charles Ryan

Details
Alicia Morgans, Charles Ryan, and Neal Shore discuss the clinical evidence and considerations in treating prostate cancer progression as patients fail first-line treatment in the nmCRPC and advance to metastatic castration-resistant prostate cancer (mCRPC). They highlight the need to change the mechanism of action and the opportunities that each Sipuleucel-T, (Provenge®) an autologous cellular imm...

The Changing Therapeutic Landscape of Prostate Cancer- Nicholas Vogelzang

Details
Dr. Nick Vogelzang discusses a brief history of the advancements in treating prostate cancer. He provides background on how we have arrived at where we are now with the advances in both the diagnosis and treatment of prostate cancer while talking with Alicia Morgans. Dr. Vogelzang reflects upon the time when we were relegated to using primitive bone scans to define disease to the current era of ad...
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe